CARMENCITA TEXON: Open Payments
NPI 1225725328 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$642 in 25 payments from 10 companies in 2025. Trend: 2023 $337 · 2024 $787 · 2025 $642
Food & beverage: $642
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 8 | $139 |
| Intercept Pharmaceuticals, Inc. | 1 | $118 |
| Regeneron Healthcare Solutions, Inc. | 4 | $101 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $78 |
| GENZYME CORPORATION | 2 | $49 |
| Janssen Biotech, Inc. | 2 | $48 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $42 |
| Medtronic, Inc. | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
| Madrigal Pharmaceuticals | 1 | $22 |
Products named: DUPIXENT, OCALIVA, LINZESS, ENTYVIO, TREMFYA, RINVOQ, GATTEX, MANOSCAN.
Industry payments across TX — which companies pay providers there.
